Clinical Trial Search

Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…

Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants

Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities

Primary: Number of Patients With Severe Toxicities — 1; 1; 1; 1 Participants

Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05

Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects

Primary: Number of Participants Who Completed Maintenance Decitabine. — 62 participants

Primary: Rate of Disease Free Survival at One Year — 50 percentage of participants

Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…

Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants

Primary: Relapse-free Survival (RFS) — 21.5 Months

Primary: Complete Response Rate — 19 Participants

Primary: Number of Patients Who Relapsed — 5; 2; 0; 1 Participants

Primary: Time to Relapse (TTR) — 12.14 months

Primary: 2-year Disease-free Survival (DFS) — 39; 50 Percentage of population — p=<0.001

Primary: Complete Response (CR) Rate — 98; 4; 9; 7 Participants

Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients

Primary: Minimal Residual Disease (MRD). — 31; 43; 68; 63 participants — p=.1559

Primary: Number of Participants With Relapse-Free Response at 1 Year — 10; 10 participants

Primary: Feasibility of Successfully Generating CIML NK Cells With Standard of Care (SOC) DLI From the Original Stem Cell Donor as Measured by the Number of Participants That Had…

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0 Participants

Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg

Primary: Occurrence of Dose Limiting Toxicities — 0; 0; 0 participants

Primary: Number of Patients With 2-year Relapse Risk — 10 Participants

Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants

Primary: Participants With a Complete Response — 34 Participants

Primary: Compare Differences in HRQOL Scores Between Outpatient Versus Inpatient Management — 70.1; 68.7 score on a scale

Primary: Number of Participants With Molecular Response — 8; 0; 4 Participants

Primary: Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS) — 36 Percentage of…

Primary: Day 22 Minimal Residual Disease (MRD) Measured by Flow Cytometry — 42; 57; 79; 64 Participants — p=0.035